Dr. Madhav Danthala Consultant Hemato-Oncologist and Bone Marrow Transplant Physician

Dr. Madhav Danthala

Dr. Madhav Danthala

MD, DM (Medical Oncology, NIMS), Fellowship in Leukemia and Bone Marrow Transplantation (Canada)

Department: Hematology & BMT
Designation: Consultant Hemato-Oncologist and Bone Marrow Transplant Physician
Years Of Experience: 11
Location: Somajiguda
Languages: Telugu, English, Hindi, Tamil, Kannada
Book An Appointment

Dr. Madhav Danthala is a Consultant Hemato-Oncologist and Bone Marrow Transplant Physician at Yashoda Hospitals, Somajiguda. He has over 10 years of experience in the fields of Hemato-Oncology/Blood Cancers and Bone Marrow Transplants.

Education Qualifications

Education Qualifications

  • 2019-2020: Fellowship in Leukemia and Bone Marrow Transplantation, Vancouver General Hospital, University of British Columbia, Canada
  • 2018-2019: Operational Research Certificate Course, WHO, SORT IT, The Union
  • 2014-2017: DM (Medical Oncology), Nizam’s Institute of Medical Sciences, Hyderabad
  • 2010-2013: MD (Internal Medicine), Sri Devaraj Urs Medical College, Kolar, Karnataka
  • 2003-2009: MBBS, PES Institute of Medical Sciences and Research, Kuppam, Andhra Pradesh 
  • Feb 2022-Present: Consultant Hemato-Oncologist and Bone Marrow Transplant Physician, Yashoda Hospitals, Somajiguda
  • July 2019-Aug 2020: Clinical Fellow Leukemia and Bone Marrow Transplant, Vancouver General Hospital, Canada
  • Sep 2017-Jan 2022: Consultant Hemato-Oncologist and BMT Physician, Manipal Hospitals, Vijayawada, Andhra Pradesh
  • June 2013-Nov 2013: Resident Doctor, Department of Medical Oncology, HCG Cancer Center, Bengaluru
Special Interest and ExpertiseSpecial Interest and Expertise
  • Blood Cancers (Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Lymphoma)
  • Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MPN)
  • Blood Disorders (Anemia, Thalassemia, Sickle Cell Anemia)
  • Autologous and Allogeneic Stem Cell Transplants (Matched Sibling Donor, Matched/Mismatched Unrelated Donor, Haploidentical Donor, Cord Blood Transplants)
  • Childhood Cancers
  • Immunotherapy
  • Targeted Therapy
  • Cellular Therapy (CAR-T Cells)
Professional MembershipProfessional Membership
  • Medical Oncology Forum (MOF)
  • Collaborative Medical Oncology Group (CMOG)
Research & PublicationsResearch & Publications
  • Danthala M, Kallur KG, Prashant GR, Rajkumar K, Rao MR. 177 Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years experience from a tertiary cancer care centre in India. European Journal of Nuclear Medicine and Molecular Imaging. 2014 Jul;41(7):1319-26.
  • Danthala M, Gundeti S, Kuruva SP, Puligundla KC, Adusumilli P, Karnam AP, Bala S, Konatam ML, Maddali LS, Digumarti RR. Generic imatinib in chronic myeloid leukemia: survival of the cheapest. Clinical Lymphoma Myeloma and Leukemia. 2017 Jul 1;17(7):457-62.
  • Danthala M, Golamari KR, Seshachalam A, Mikkilineni A, Chappidi S, Mekala MB, Elangovan V, Chinnakali P. Walking a Tightrope: Dosage Modifications and Treatment Outcomes of All Trans-Retinoic Acid, Arsenic Trioxide, and Daunorubicin for HighRisk Acute Promyelocytic Leukemia. JCO Global Oncology. 2020 Nov;6:1749-56.
  • Danthala M, Gundeti S, Maddali LS, Pillai A, Puligundla KC, Adusumilli RP. Philadelphia chromosome-positive acute lymphoblastic leukaemia: 8 years experience from a tertiary care center in India. South Asian Journal of Cancer. 2016 Oct;5(04):176-8.
  • Karpurmath SV, Seshachalam A, Selvaraj K, Rajamani P, Reddy N, Malipatil B, Sirigeri R, Prasad K, Reddy K, Danthala M, Udupa KS. Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value—A Multicenter Study from South India. Clinical Lymphoma Myeloma and Leukemia. 2020 May 1;20(5):e205-11.
  • Seshachalam A, Karpurmath SV, Rathnam K, Raman SG, Janarthinakani M, Prasad K, Patil C, Anoop P, Reddy N, Anumula SK, Roopa SP, Danthala M. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence. Journal of Global Oncology. 2019 Dec;5:1-3.
  • Adusumilli P, Gundeti S, Danthala M, Pk C. 301P Long term survival and late side effects of paediatric Hodgkin lymphoma patients: a study from a tertiary care centre in Southern India. Annals of Oncology. 2015 Dec 1;26(suppl_9):ix89. 
  • Puligundla CK, Gundeti S, Bala S, Pillai A, Adusumilli P, Danthala M, Konatam ML, Maddali LS. Mutation Analysis and Treatment Outcomes of BCR-ABL Tyrosine Kinase Domain in CML Patients with Imatinib Treatment Failure-Data from a Large Tertiary Center in India. Blood 2016 vol: 128 (22) pp: 1910-1910.
  • Danthala M, Rajesh GR, Gundeti S, Raju GS, Chandran P, Srinivas ML. Obesity and Breast Cancer: Association of serum adiponectin, leptin, and adiponectin–leptin ratio as risk biomarkers. Indian Journal of Medical and Paediatric Oncology. 2018 Jul;39(03):292-6.
  • Danthala M, Lakshmaiah V. Correlative study of serum cystatin C levels with severity of acute ischemic stroke. J Clin Biomed Sci. 2013;3(4):188-92.
  • Naveen L, Santoshi M, Madhav D, Sri Rama AG, Mahesh V. A study of the association of insulin resistance and cardiometabolic risk factors in an adult population with type 2 diabetes mellitus, Inter. J. Appl. Med. Sci. 2014;4:168-72.
Education QualificationsPosters/papers/oral Presentations
  • Proffered Paper: Additional chromosomal abnormalities in chronic myeloid leukemia: lest we forget. Presented at ESMO (European Society of Medical Oncology) Asia 2016, Singapore
  • Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest. Presented at ASH 2016 (Annual American Society of Hematology Conference), San Diego. Shortlisted for Best of ASH
  • Microalbuminuric anemia: A study of the relationship between hemoglobin levels and albuminuria in diabetes. KAPICON 2012
  • Obesity and breast cancer: Association of serum adiponectin, leptin and adiponectin-leptin ratio as risk biomarkers. Presented  at Annual Indian Society of Medical and Pediatric Oncology Conference, 2016 at Delhi
  • Renal Reversibility in Multiple Myeloma: A race against the clock! Presented at Myeloma: State of the Art, 2016, PGI Chandigarh
  • Philadelphia chromosome-positive acute lymphoblastic leukemia: 8 years’ experience from a tertiary care center in India. Presented at Annual Asian Clinical Oncology Society Conference 2016, Delhi
  • Validation of an enhanced International Prognostic Index (NCCN IPI) in patients with diffuse large B cell lymphoma in the Rituximab era: 7 years’ experience from a tertiary care center in  South India. Presented at ICON 2016, received the Best Poster Presentation Award
  • Frontline Imatinib in Chronic Myeloid Leukemia: A Jewel in the Crown, Presented at Hematocon 2016, Jaipur
  • Pediatric chronic myeloid leukemia: wise to generalize? Presented at ISMPOCON 2016, Delhi
  • Monosomy 7 and Deletion 7q in Acute Myeloid Leukemia – M0/ M1 with prior Myelodysplastic syndrome transformed from Fanconi Anemia – a case report. HEMATOCON 2015
  • Phenytoin induced Cerebellar Ataxia and Orofacial Dyskinesia in  a rare case of Disseminated Cysticercosis. APICON 2013
Awards and AchievementsAwards and Achievements
  • Instrumental in successfully setting up the Allogeneic Stem Cell Transplant Program at Manipal Hospitals, Vijayawada and performed more than 50 Stem Cell Transplants, the highest in the state.
  • Performed the First Matched Sibling Donor and Haploidentical Stem Cell Transplant in Andhra Pradesh
  • University Topper (SDUAHER) Internal Medicine (2013)
  • 1st Rank, DM Medical Oncology Entrance Examination, Nizam’s Institute of Medical Sciences

Diet during Cancer Treatment | Dr. Madhav Danthala, Consultant Hemato-Oncologist and Bone Marrow Transplant Physician

మీరు బ్ల‌డ్ క్యాన్స‌ర్‎తో బాధ‌ప‌డుతున్నారా? | Dr. Madhav Danthala, Consultant Hemato-Oncologist and Bone Marrow Transplant Physician

Blogs by Dr. Madhav Danthala

Matchmaking-Donors in Stem Cell Transplants

Matchmaking-Donors in Stem Cell Transplants

Apr 08, 2022 21:31

A bone marrow transplant is a medical procedure that replaces bone marrow with healthy replacement cells that can be taken either from a patient’s body or from a donor.

Read More..

Select Department
Not Sure of the Specialty?

Choose your date & Slot

Change Date
Monday, OCTOBER 30
Enter Patient Details

Please Note: This session ends in 3:00 mins

Not Finding Your Preferred Slots?